Nirsevimab effectiveness against RSV hospitalizations in children 8-23 months at risk of severe RSV

Importance: Respiratory syncytial virus (RSV) is a leading cause of hospitalization in high-risk young children during their second RSV season. Nirsevimab, a long-acting monoclonal antibody against RSV, is recommended for some children who are at increased risk for severe RSV and entering their second RSV season to prevent severe RSV disease. Because of limited eligibility criteria for second season nirsevimab, estimating its effectiveness is challenging. Objective: We evaluated nirsevimab effectiveness against RSV-associated hospitalizations among young children eligible to receive nirsevimab during their second RSV season. Design: This retrospective case control study with a test-negative design was conducted during the 2024-2025 and 2025-2026 RSV seasons. Setting: Enrollment was in 26 hospitals across 24 U.S. states. Participants: Children eligible for nirsevimab during their second RSV season (as recommended in August 2023) were included. Nirsevimab-eligible children 8-23 months old hospitalized with respiratory symptoms were enrolled. Case-patients tested positive for RSV; control-patients tested negative for RSV. Exposures: Receipt of nirsevimab before or during the second RSV season and at least 7 days before symptom onset. Outcomes and measures: RSV-associated hospitalization. We estimated nirsevimab effectiveness using multivariable logistic regression adjusted for age, month and year of hospitalization, census region, and sex comparing the odds of second season nirsevimab receipt among case- and control-patients. Results: One hundred six case-patients and 125 control-patients were analyzed. Distributions of age, sex, race and ethnicity, and region were similar in case- and control-patients. Most case- and control-patients were eligible for nirsevimab because of chronic lung disease of prematurity (84.0% and 69.6%, respectively). Overall, 21 (19.8%) of case-patients and 53 (42.4%) of control-patients received nirsevimab. Adjusted nirsevimab effectiveness against RSV-associated hospitalizations was 78.1% (95% CI, 55.2%-89.3%); the median interval from nirsevimab receipt to symptom onset was 66.5 days (IQR = 30-96 days). Effectiveness was estimated to be higher if nirsevimab was received 8-59 days before symptom onset (88.5%, 95% CI, 63.4%-96.4%). Conclusions: This analysis provides real-world estimates of substantial nirsevimab effectiveness against RSV-associated hospitalizations for high-risk U.S. children in their second RSV season These data support recommendations for nirsevimab as a preventive strategy in this population.

Authors

Institutions

Publication Details

Journal
medRxiv
Published
2026-11-16
DOI
https://doi.org/10.64898/2026.11.13.26368017
Primary Topic
Respiratory viral infections research
Type
preprint
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
preprint

Nirsevimab effectiveness against RSV hospitalizations in children 8-23 months at risk of severe RSV

Satoshi Kamidani, Margaret M. Newhams, Katherine Irby, Austin Biggs et al.
8 links
medRxiv
Respiratory viral infections research
preprint

Nirsevimab effectiveness against RSV hospitalizations in children 8-23 months at risk of severe RSV

Satoshi Kamidani, Margaret M. Newhams, Katherine Irby, Austin Biggs, Regina M. Simeone, Samina S. Bhumbra, Aline B. Maddux, Mary Allen Staat, Emily R. Levy, Tracie C. Walker, Neelima K. Marupudi, Melissa S. Stockwell, Amanda B. Payne, Angela P. Campbell, Kelly Nicole Michelson, Amber O. Orzel-Lockwood, Kong Michele, Lora Martin, Jigar Chauhan, Jennifer Schuster, Overcoming RSV Network investigators, Judith Guzman-Cottrill, Tamara Brandford, Hillary Crandall, Samina Bhumbra, Kathleen Chiotos, Natasha Halasa, Janet Hume, Jemima Calixte, Adrienne Randolph, Alexander H Hogan, Danielle Zerr, Melissa Cameron
preprint en

Abstract

Importance: Respiratory syncytial virus (RSV) is a leading cause of hospitalization in high-risk young children during their second RSV season. Nirsevimab, a long-acting monoclonal antibody against RSV, is recommended for some children who are at increased risk for severe RSV and entering their second RSV season to prevent severe RSV disease. Because of limited eligibility criteria for second season nirsevimab, estimating its effectiveness is challenging. Objective: We evaluated nirsevimab effectiveness against RSV-associated hospitalizations among young children eligible to receive nirsevimab during their second RSV season. Design: This retrospective case control study with a test-negative design was conducted during the 2024-2025 and 2025-2026 RSV seasons. Setting: Enrollment was in 26 hospitals across 24 U.S. states. Participants: Children eligible for nirsevimab during their second RSV season (as recommended in August 2023) were included. Nirsevimab-eligible children 8-23 months old hospitalized with respiratory symptoms were enrolled. Case-patients tested positive for RSV; control-patients tested negative for RSV. Exposures: Receipt of nirsevimab before or during the second RSV season and at least 7 days before symptom onset. Outcomes and measures: RSV-associated hospitalization. We estimated nirsevimab effectiveness using multivariable logistic regression adjusted for age, month and year of hospitalization, census region, and sex comparing the odds of second season nirsevimab receipt among case- and control-patients. Results: One hundred six case-patients and 125 control-patients were analyzed. Distributions of age, sex, race and ethnicity, and region were similar in case- and control-patients. Most case- and control-patients were eligible for nirsevimab because of chronic lung disease of prematurity (84.0% and 69.6%, respectively). Overall, 21 (19.8%) of case-patients and 53 (42.4%) of control-patients received nirsevimab. Adjusted nirsevimab effectiveness against RSV-associated hospitalizations was 78.1% (95% CI, 55.2%-89.3%); the median interval from nirsevimab receipt to symptom onset was 66.5 days (IQR = 30-96 days). Effectiveness was estimated to be higher if nirsevimab was received 8-59 days before symptom onset (88.5%, 95% CI, 63.4%-96.4%). Conclusions: This analysis provides real-world estimates of substantial nirsevimab effectiveness against RSV-associated hospitalizations for high-risk U.S. children in their second RSV season These data support recommendations for nirsevimab as a preventive strategy in this population.

medRxiv
University of North Carolina at Chapel Hill (US), Louisiana State University (US), Cincinnati Children's Hospital Medical Center (US), Boston Children's Hospital (US), Centers for Disease Control and Prevention (US), Lurie Children's Hospital (US), Arkansas Children's Hospital (US), University of Minnesota (US), Primary Children's Hospital (US), Alfred I. duPont Hospital for Children (US), Children's Mercy Hospital (US), Mayo Clinic (US), Children's Hospital of Philadelphia (US), Harvard University (US), University of Arizona (US), Emory University (US), Medical University of South Carolina (US), Oregon Health & Science University (US), University of California, San Francisco (US), National Center for Immunization and Respiratory Diseases (US), University of Washington (US), University of Utah (US), Community Health Systems - Dupont Hospital (US), University of Mississippi Medical Center (US), University of Alabama at Birmingham (US), University of California San Diego (US), Rady Children's Hospital-San Diego (US), Children's Hospital Colorado (US), Connecticut Children's Medical Center (US), Banner Desert Medical Center (US), Nemours Children's Health System (US), Seattle Children's Hospital (US), Children's Hospital of New Orleans (US), University of North Carolina Hospitals (US), Lurie Children's Hospital (US), Children's Healthcare of Atlanta (US), University of Utah Health Care (US), Center for Pain and the Brain (US), Banner Children's at Desert (US), University of Minnesota Children's Hospital (US), Indiana University Indianapolis (US), UAB Medicine (US), Indiana University School of Medicine (US), Seattle Children's Research Institute (US), University of Colorado Anschutz Medical Campus (US), Indiana University – Purdue University Indianapolis (US), University of Cincinnati (US), Louisiana State University Health Sciences Center New Orleans (US), University of Missouri–Kansas City (US), Columbia University (US), Vanderbilt University Medical Center (US), University of Colorado Denver (US)
Good health and well-being
Respiratory viral infections research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon